Register Login

MINK THERAPEUTICS, INC. (INKT)

(80% Positive) MINK THERAPEUTICS, INC. (INKT) Announces Enrollment Update for authorization Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Aug. 13, 2026, 12:30 p.m.

    📋 MINK THERAPEUTICS, INC. (INKT) - Clinical Trial Update

    Filing Date: 2026-08-13

    Accepted: 2026-08-13 07:40:44

    Event Type: Clinical Trial Update

    Event Details:

    MINK THERAPEUTICS, INC. (INKT) Announces Clinical Trial Update MINK THERAPEUTICS, INC. (INKT) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: authorization, established
    • Diseases/Conditions: physicians to request access to agenT-797, Ukraine
    • Clinical Stage: Phase 2 trial, Phase 2
    • Collaboration: Ministry of Health
      • expected in early 2027

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: MINK THERAPEUTICS, INC.
    • Ticker Symbol: INKT

Search

News categories